Long-term follow-up of EXG102-031 treatment for wet age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational follow-up enrolls participants who previously received an EXG102-031 injection in the parent EXG102-031-111 protocol and obtains informed consent for continued monitoring. No new interventions are given; visits continue the assessments from the parent study to capture safety and durability data. Visits occur every two months for the first two years and every six months from years three to five, focusing on ocular exams and functional outcomes. Continuous safety monitoring and collection of efficacy-related measures will inform long-term risk and benefit profiles for the therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);
2. Paticipantes are informed consent and willingness to follow protocol procedures.

Exclusion Criteria:

1\. Paticipantes are unwilling or unable to participate in long-term follow-up

Where it's running

• Peking University People's Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Mingwei ZHAO, PhD — Peking University People's Hospital
• Study coordinator: Sara Yang, MD
• Email: sarayang@exegenesisbio.com
• Phone: +86 13957164092

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Topical NT-101 in wet age-related macular degeneration

  A topical eye drop (NT-101) is being tested to see if it can help people 50 and older with wet AMD when used twice daily for 12 weeks.

  Recruiting at 3 sites Phase 2 NexThera Co., Ltd. · Bonita Springs, Florida and 2 other locations · NCT07811726

• Comparing 8-week and 12-week follow-up intervals for treating wet AMD with faricimab

  This study is testing whether patients with wet age-related macular degeneration can benefit more from follow-up treatments every 8 weeks or every 12 weeks after their initial injections of faricimab.

  Recruiting Phase 4 Faculty Hospital Kralovske Vinohrady · Prague · NCT06875245

• Low-dose oral doxycycline targeting MMP-9 for persistent wet AMD

  This trial tests whether taking low-dose doxycycline daily can help people with wet AMD who still have sub-retinal fluid despite regular anti-VEGF eye injections.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT04504123

• EYC-0305 in Neovascular (Wet) AMD: First-in-Patients Safety and Tolerability Study

  This study tests whether EYC-0305 given as an eye injection every 24 weeks is safe and tolerable in people 50 and older with wet AMD.

  Recruiting at 7 sites Phase 1/2 Eyconis INC. · Beverly Hills, California and 6 other locations · NCT07587515

• AIV007 Periocular Shot for Wet AMD

  This trial tests whether a periocular injection of AIV007 can improve vision and safety in people with wet age-related macular degeneration, compared with the standard Eylea injections.

  Recruiting at 2 sites Phase 2 AiViva BioPharma, Inc. · Torrance, California and 1 other locations · NCT07557121

• Long-term follow-up for patients with wet age-related macular degeneration receiving SKG0106

  This study is testing how well and safely the treatment SKG0106 works for people with wet age-related macular degeneration over a long period after their last injection.

  Recruiting at 2 sites Skyline Therapeutics · Boston, Massachusetts and 9 other locations · NCT06346600

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.